Latest News
Alliance Pharma acquires antimalarial brands from AstraZeneca
2 August 2012 - Speciality pharmaceutical company Alliance Pharma plc (AIM:APH) announced today the acquisition of three antimalarial brands from Anglo-Swedish pharmaceutical company AstraZeneca plc (LSE:AZN) (STO:AZN) (NYSE:AZN).

Alliance Pharmaceuticals Limited, a wholly owned subsidiary of Alliance Pharma, is paying an initial GBP4.2m to purchase the brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. These products are sold mainly in the UK and France.

In a statement, Alliance said that it expects the acquired products to generate incremental contribution before financing costs of approximately GBP1.1m per annum.

On top of the initial cash consideration of GBP4.2m, a further sum of up to GBP1.0m may become payable over the next three years, dependent on sales of the brands.

Alliance also announced that it has recently appointed a country manager for France, Dr Philippe Pasdelou, who will manage the sales of the anti-malarial brands in France. The company has also appointed Lars Borger as country manager for Germany, Switzerland and Austria.

(USD1=GBP0.64)

Login
Username:

Password: